Rexahn Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference Aug 30, 2018
Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin™) in combination with KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer Aug 21, 2018
Rexahn Announces Adjournment of Annual Meeting of Shareholders until Wednesday, June 27, 2018 Jun 14, 2018
Rexahn Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting Jun 4, 2018
Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage May 15, 2018
Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting Apr 26, 2018
